V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310003482 | 310001459 | 1.71 | 76 | Palliative (P) | 2015-11-19 | 2015-11-19 | Ipilimumab | 02 | null | 310018026 | IPILIMUMAB |
| 310003483 | 310001460 | 1.82 | 115 | Palliative (P) | 2013-12-23 | 2013-12-23 | PEMBROLIZUMAB | 2 | N | 310018034 | PEMBROLIZUMAB |
| 310003484 | 310001461 | 1.69 | 94 | Not known (9) | 2014-09-18 | 2014-09-26 | Carboplatin + Etoposide iv&po | 2 | N | 310018035 | CARBOPLATIN + ETOPOSIDE |
| 310003485 | 310001462 | 1.6 | 52 | Palliative (P) | 2017-06-10 | 2017-06-26 | CISPLATIN + GEMCITABINE | N | N | 310018037 | CISPLATIN + GEMCITABINE |
| 310003486 | 310006624 | null | 96.3 | Palliative (P) | 2018-01-10 | 2018-02-02 | CHOP R - 21 days | N | N | 310018039 | CHOP R |
| 310003487 | 310001463 | 1.71 | 83 | Neo-adjuvant (N) | 2015-03-16 | 2015-03-30 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 310018042 | CISPLATIN + GEMCITABINE |
| 310003488 | 310001463 | null | 87 | Palliative (P) | 2017-12-19 | 2017-12-19 | Selumetinib | 1 | N | 310018042 | TRIAL |
| 310003489 | 310001464 | 1.76 | 93.6 | Palliative (P) | 2017-06-19 | 2017-06-20 | CISPLATIN + GEMCITABINE | 02 | N | 310018047 | CISPLATIN + GEMCITABINE |
| 310003490 | 310001465 | 1.67 | 91.7 | Curative (C) | 2013-08-24 | 2013-08-24 | CHOP R - 21 days | 2 | N | 310018048 | CHOP R |
| 310003491 | 310001466 | 1.74 | 129 | Adjuvant (A) | null | 2013-10-13 | Cisplatin 7 day | N | Y | 310018051 | CISPLATIN |
| 310003492 | 310001466 | 1.7 | 64.5 | Curative (C) | 2017-06-19 | 2017-07-11 | Cisplatin 7 day | N | Y | 310018051 | CISPLATIN |
| 310003493 | 310009060 | null | 83.4 | Palliative (P) | 2013-09-06 | 2013-09-06 | Ipilimumab | 2 | N | 310018058 | IPILIMUMAB |
| 310003494 | 310009060 | null | 54.9 | Curative (C) | 2015-11-08 | 2015-11-17 | Retinoblastoma JOE | null | N | 310018058 | CEV |
| 310003495 | 310011043 | 1.55 | 85 | Palliative (P) | 2015-09-15 | 2015-09-24 | Carboplatin + Etoposide iv&po | N | N | 310018064 | CARBOPLATIN + ETOPOSIDE |
| 310003496 | 310001467 | null | 76.4 | Curative (C) | 2013-07-17 | 2013-07-28 | Retinoblastoma JOE | N | N | 310018066 | CEV |
| 310003497 | 310001468 | null | 94.5 | Curative (C) | 2013-05-24 | 2013-05-29 | Retinoblastoma JOE | N | N | 310018069 | CEV |
| 310003498 | 310001469 | 1.85 | 97.1 | Curative (C) | 2015-10-04 | 2015-10-07 | CHOP R - 21 days | N | N | 310018070 | CHOP R |
| 310003499 | 310006627 | null | 91.7 | Adjuvant (A) | 2013-08-29 | 2013-09-03 | Cisplatin + Gemcitabine (D 1 & 8) | N | 2 | 310018077 | CISPLATIN + GEMCITABINE |
| 310003500 | 310006627 | 1.63 | null | Disease modification (D) | 2017-12-17 | 2018-01-01 | Trial Unspecified | Y | N | 310018077 | TRIAL |
| 310003501 | 310006627 | 1.79 | 86.4 | Palliative (P) | 2016-11-02 | 2016-11-03 | Doxorubicin 75mg/m2 | N | N | 310018077 | DOXORUBICIN |
| 310003502 | 310011044 | 1.63 | 72.1 | Curative (C) | 2018-06-12 | 2018-06-19 | Trial Unspecified | N | N | 310018081 | TRIAL |
| 310003503 | 310001470 | 1.61 | 70.3 | Palliative (P) | 2017-07-11 | 2017-07-12 | Trial Unspecified | 1 | N | 310018083 | TRIAL |
| 310003504 | 310001471 | 1.76 | 85.8 | Curative (C) | 2017-12-13 | 2017-12-21 | Cisplatin | 2 | Y | 310018084 | CISPLATIN |
| 310003511 | 310001473 | null | 77 | Curative (C) | 2016-09-07 | 2016-09-10 | CHOP R - 21 days | N | N | 310018107 | CHOP R |
| 310003512 | 310006629 | 1.62 | 83 | Palliative (P) | 2015-12-24 | 2015-12-28 | Ipilimumab | N | N | 310018110 | IPILIMUMAB |
| 310003513 | 310006629 | 1.81 | 76 | Palliative (P) | 2018-03-23 | 2018-03-23 | PEMBROLIZUMAB | 02 | N | 310018110 | PEMBROLIZUMAB |
| 310003514 | 310001474 | null | 84 | Curative (C) | 2016-02-13 | 2016-02-13 | Retinoblastoma JOE | N | N | 310018113 | CEV |
| 310003515 | 310001475 | 1.71 | 87.5 | null | 2017-01-04 | 2017-01-07 | CHOP R - 21 days | 2 | N | 310018114 | CHOP R |
| 310003516 | 310001475 | 1.61 | 85 | Curative (C) | null | 2015-01-10 | Cisplatin | N | Y | 310018114 | CISPLATIN |
| 310003517 | 310001476 | null | 57.6 | Palliative (P) | null | 2017-03-13 | Ipilimumab | null | null | 310018116 | IPILIMUMAB |
| 310003518 | 310006631 | 1.82 | 88.6 | Curative (C) | 2017-12-30 | 2017-12-31 | CARBOPLATIN + ETOPOSIDE | N | N | 310018118 | CARBOPLATIN + ETOPOSIDE |
| 310003522 | 310010340 | 1.74 | 57 | Palliative (P) | 2016-01-18 | 2016-01-27 | Trial Unspecified | N | N | 310018124 | TRIAL |
| 310003523 | 310001478 | 1.65 | null | Palliative (P) | 2017-12-19 | 2017-12-20 | DOXORUBICIN | N | null | 310018125 | DOXORUBICIN |
| 310003524 | 310001478 | 1.6 | 89 | Palliative (P) | 2017-02-15 | 2017-02-15 | Ipilimumab | 02 | N | 310018125 | IPILIMUMAB |
| 310003525 | 310001478 | 1.75 | null | Palliative (P) | 2016-06-27 | 2016-06-27 | PEMBROLIZUMAB | N | N | 310018125 | PEMBROLIZUMAB |
| 310003526 | 310001479 | 1.72 | 104.2 | Palliative (P) | 2017-09-27 | 2017-10-09 | Ipilimumab | 02 | N | 310018131 | IPILIMUMAB |
| 310003527 | 310001479 | 1.65 | 49.4 | Curative (C) | 2016-06-09 | 2016-06-24 | CHOP R - 21 days | N | N | 310018131 | CHOP R |
| 310003528 | 310001480 | 1.65 | null | Palliative (P) | 2018-01-22 | 2018-01-23 | Cisplatin + Gemcitabine (D 1 & 8) | N | null | 310018133 | CISPLATIN + GEMCITABINE |
| 310003529 | 310001480 | 1.84 | 119 | Palliative (P) | 2014-08-28 | 2014-09-02 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 310018133 | CISPLATIN + GEMCITABINE |
| 310003530 | 310001480 | 1.82 | 60 | Not known (9) | 2016-10-28 | 2016-11-19 | CARBOPLATIN + ETOPOSIDE | N | N | 310018133 | CARBOPLATIN + ETOPOSIDE |
| 310003531 | 310001480 | 1.67 | null | null | null | 2017-10-15 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 310018133 | CISPLATIN + GEMCITABINE |
| 310003532 | 310001480 | 1.75 | 47.4 | Palliative (P) | 2018-03-17 | 2018-03-17 | PEMBROLIZUMAB | 02 | N | 310018133 | PEMBROLIZUMAB |
| 310003533 | 310001481 | 1.81 | 76.7 | null | 2015-03-06 | 2015-03-06 | Trial Unspecified | 01 | N | 310018144 | TRIAL |
| 310003534 | 310001481 | 1.61 | 68 | Curative (C) | null | 2014-08-05 | Cisplatin 7 day | null | Y | 310018144 | CISPLATIN |
| 310003535 | 310001482 | 1.74 | 13.7 | Palliative (P) | 2018-11-22 | 2018-11-22 | DOXORUBICIN | N | N | 310018147 | DOXORUBICIN |
| 310003536 | 310001483 | null | 87.1 | Curative (C) | 2015-07-11 | 2015-08-29 | CHEMO-T TRIAL | Y | N | 310018149 | TRIAL |
| 310003537 | 310001483 | 1.89 | 92 | Palliative (P) | 2014-07-16 | 2014-07-19 | PEMBROLIZUMAB | N | N | 310018149 | PEMBROLIZUMAB |
| 310003538 | 310001483 | 0 | 11.9 | Curative (C) | 2013-04-20 | 2013-04-20 | Retinoblastoma JOE | N | N | 310018149 | CEV |
| 310003539 | 310001483 | 1.68 | 83.35 | Curative (C) | 2017-07-05 | 2017-07-13 | Cisplatin 7 day | 2 | Y | 310018149 | CISPLATIN |
| 310003540 | 310001483 | 0 | 72.5 | Curative (C) | 2016-08-18 | 2016-08-30 | Retinoblastoma JOE | N | N | 310018149 | CEV |